Literature DB >> 9257768

In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles.

F Barchiesi1, L Falconi Di Francesco, G Scalise.   

Abstract

A checkerboard microdilution method was applied to study the in vitro interaction of terbinafine with either fluconazole and itraconazole against 30 strains of Candida albicans. Synergy was observed in 40% of the terbinafine-fluconazole interactions and in 43% of the terbinafine-itraconazole interactions, while antagonism was not observed. Even when only additivity was achieved, the combinations still showed beneficial effects since at least twofold reductions in the MICs of both drugs were found in 100% of the terbinafine-fluconazole interactions and in 76% of the terbinafine-itraconazole interactions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9257768      PMCID: PMC164012     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model.

Authors:  F Barchiesi; L K Najvar; M F Luther; G Scalise; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

Authors:  S Redding; J Smith; G Farinacci; M Rinaldi; A Fothergill; J Rhine-Chalberg; M Pfaller
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

3.  Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole.

Authors:  J H Rex; M A Pfaller; M Lancaster; F C Odds; A Bolmström; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

4.  Fluconazole-resistant Candida albicans after long-term suppressive therapy.

Authors:  A Sanguineti; J K Carmichael; K Campbell
Journal:  Arch Intern Med       Date:  1993-05-10

5.  Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans.

Authors:  F Barchiesi; M Del Poeta; V Morbiducci; F Ancarani; G Scalise
Journal:  Mycopathologia       Date:  1993-10       Impact factor: 2.574

Review 6.  Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.

Authors:  J A Balfour; D Faulds
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

7.  In-vitro synergy testing of triple antibiotic combinations against Staphylococcus epidermidis isolates from patients with endocarditis.

Authors:  V L Yu; J J Zuravleff; J Bornholm; G Archer
Journal:  J Antimicrob Chemother       Date:  1984-10       Impact factor: 5.790

8.  Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods.

Authors:  M A Pfaller; M Bale; B Buschelman; M Lancaster; A Espinel-Ingroff; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

9.  Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading.

Authors:  E Anaissie; V Paetznick; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

10.  Fluconazole-resistant Candida albicans.

Authors:  D J Boken; S Swindells; M G Rinaldi
Journal:  Clin Infect Dis       Date:  1993-12       Impact factor: 9.079

View more
  24 in total

1.  In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.

Authors:  Eric Dannaoui; Javier Afeltra; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 2.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans.

Authors:  J Meletiadis; J W Mouton; J L Rodriguez-Tudela; J F Meis; P E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Angel Viudes; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole.

Authors:  Hua Quan; Ying-Ying Cao; Zheng Xu; Jing-Xia Zhao; Ping-Hui Gao; Xiao-Feng Qin; Yuan-Ying Jiang
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

6.  Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model.

Authors:  Michael J Dolton; Vidya Perera; Lisa G Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

7.  Comparative evaluation of a new commercial colorimetric microdilution assay (SensiQuattro Candida EU) with MIC test strip and EUCAST broth microdilution methods for susceptibility testing of invasive Candida isolates.

Authors:  Hedda Luise Koehling; Birgit Willinger; Jan Buer; Peter-Michael Rath; Joerg Steinmann
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

Review 8.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

9.  In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Monia Maracci; Annette W Fothergill; Isabella Baldassarri; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 10.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.